How Are Service Companies Responding to the Increased Interest in New Modalities, and What Regulatory and Market Hurdles Still Exist?

On Tuesday, April 30, 2019, Dan Stanton moderated a CPhI Theater roundtable discussion about the ways that biomanufacturers are confronting great demand for monoclonal antibody (MAb) therapies, antibody drug conjugates (ADCs), and other emerging treatments that depend on complex chemistries. Featuring Juan Cordova (Principal Scientist of Bioconjugation at Abzena), Dawn Ecker (a consultant with the BioProcess Technology Group at BDO), and Scott Miller (Senior Scientific Advisor at Carbogen Amcis AG), this panel explored current challenges to upstream processing for antibody therapies. Panelists then imagined how these difficulties might increase as the industry pursues genes, mRNA strands, and CAR T cells.

Watch the full roundtable discussion below and leave your thoughts or questions on the topic below in the comments.

Leave a Reply